CBS (CBS) is lower on Thursday, but Wells Fargo thinks investors are wrong to overlook the media giant.
Analyst Marci Ryvicker and her team reiterated an Outperform rating and raised her valuation on the stock to $75 to $80, from a previous range of $72 to $76.
She writes that plenty of investors have strong opinions about Disney (DIS), 21st Century Fox (FOXA), and Viacom (VIAB), but few show much interest in CBS, which she thinks is a mistake.
When asked why she likes the stock, she cites three main reasons:
1) We have always liked CBSs position in the ecosystem given its pure portfolio of assets (one broadcast net and one premium net) and strict focus on monetization of content. 2) We believe there could be some nice upside to 2018 estimates ($100MM of OI/$0.17 of EPS to be exact), which is nowhere in Street numbers (nor in ours). And 3) we see significant earnings power over the long term via CBSs 4 revenue pillars (remember that $3.75B)Given the potential long term upside, we do NOT think CBS should be trading at a 3x discount to the market.
Top Bank Stocks To Invest In Right Now: Cerus Corporation(CERS)
We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Our INTERCEPT Blood System is for use with three blood components: plasma, platelets, and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received a broad range of regulatory approvals, including but not limited to U.S. Food and Drug Administration, or FDA, approval in the United States of America (“U.S. Advisors’ Opinion:
- [By Shane Hupp]
Shares of Cerus Co. (NASDAQ:CERS) have received an average rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.50.
- [By Motley Fool Transcribers]
Cerus Corporation (NASDAQ:CERS)Q42018 Earnings Conference CallFeb. 26, 2019, 4:30 p.m. ET
Prepared Remarks Questions and Answers Call Participants
- [By Stephan Byrd]
Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 2,783 shares of the business’s stock in a transaction that occurred on Wednesday, October 10th. The shares were sold at an average price of $6.09, for a total transaction of $16,948.47. Following the transaction, the chief financial officer now directly owns 63,608 shares of the company’s stock, valued at $387,372.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Top Bank Stocks To Invest In Right Now: SEACOR Holdings, Inc.(CKH)
SEACOR Holdings Inc. owns, operates, invests, and markets equipment in the offshore oil and gas, shipping, and logistics industries. The companys Offshore Marine Services segment operates support vessels to deliver cargo and personnel to offshore installations; handle anchors and mooring equipment; carry and launch remote operated vehicles; and tow rigs. This segment also provides accommodations for technicians and specialists, as well as standby safety support and emergency response services; and operates lift boats supporting well intervention, work-over, decommissioning, and diving operations, as well as operates vessels used to move personnel and supplies to offshore wind farms. Its Inland River Services segment operates river transportation equipment for moving agricultural and industrial commodities, and petroleum and chemical products; and operates and invests in multi-modal terminal facilities, as well as operates barge fleeting locations; service facilities; and transshipment terminal. The companys Shipping Services segment owns product tankers for the United States coastwise trade of crude oil, petroleum, and chemical products, as well as provides harbor tugs servicing vessels docking; and invests in very large gas carriers, as well as offers liner and short-sea transportation. This segment is also involved in the terminal support and bunkering, and articulated tug and dry-bulk barge operations, as well as offers offshore tug and technical ship management services. Its Illinois Corn Processing segment produces alcohol used in the food, beverage, industrial, and petrochemical markets; dried distillers grains with solubles; and non-food grade corn oil for feedstock in biodiesel production. The companys Other segment engages in emergency and crisis, agricultural commodity trading and logistics, and lending and leasing activities, as well as industrial aviation services businesses. The company was founded in 1989 and is based in Fort Lauderdale, Florida.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Seacor (CKH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
United Services Automobile Association boosted its position in shares of Seacor Holdings, Inc. (NYSE:CKH) by 14.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 172,136 shares of the oil and gas company’s stock after buying an additional 21,997 shares during the period. United Services Automobile Association owned approximately 0.94% of Seacor worth $9,858,000 as of its most recent SEC filing.
- [By Joseph Griffin]
Headlines about Seacor (NYSE:CKH) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seacor earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the oil and gas company an impact score of 45.3315874804175 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Top Bank Stocks To Invest In Right Now: InfuSystems Holdings, Inc.(INFU)
InfuSystem Holdings, Inc., incorporated on August 15, 2005, is a provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers and other sites of care. The Company delivers local, field-based customer support and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Texas and Ontario, Canada. The Company’s core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics for the treatment of a range of cancers, including colorectal cancer, pain management and other disease states (Oncology Business). In addition, the Company sells or rents new and pre-owned pole mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings, including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the hospital market. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The Company operates through subsidiaries, including InfuSystem Holdings USA, Inc. (Holdings), InfuSystem, Inc. (ISI), First Biomedical, Inc. (First Biomedical) and IFC, LLC (IFC).
The Company bills and collects payment from payers and patients for the use of the pumps, after providing ambulatory pumps to oncology offices, infusion clinics and hospital and outpatient chemotherapy clinics. After a physician determines that a patient is eligible for ambulatory infusion pump therapy, the physician arranges for the patient to receive an infusion pump and provides the necessary chemotherapy drugs. The physician and nursing staff train the patient in the use of the pump and initiate service. The physician bills the payers, which include Medicare, Medi! caid, third party payer companies or patients for the physician’s professional services associated with initiating and supervising the infusion pump administration, as well as the supply of drugs. The Company directly bills payers and patients for copays and deductibles for the use of the pump and related disposable supplies. Billing to payers requires coordination with patients and physicians who initiate the service, as physicians’ offices must provide it with paperwork (patient’s insurance information, physician’s order, an acknowledgement of benefits that shows receipt of equipment by the patient, and, in some cases, physician’s progress notes) in order for the Company to bill the payers. The Company provides assistance to those that cannot afford its pumps through a program that matches what the physician practices provide as long as the uninsured patients meet certain criteria.
The Company provides patients with around the clock service and support. Physicians use its services to outsource the capital commitment, pump service, maintenance and billing and administrative burdens associated with pump ownership. The Company provides methods for the physician offices to deliver the paperwork for billing through a number of electronic means, including EXPRESS and InfuConnect. Its pumps are available for daily, weekly, monthly or annual rental periods. The Company also provides biomedical maintenance, repair and certification services for the devices it offers, as well as for devices owned by customers. The Company also offers electronic ambulatory infusion pumps for post-operative pain management using its pumps along with a numbing agent and a continuous nerve block catheter, continuous peripheral nerve block (CPNB).
- [By Shane Hupp]
InfuSystem Holdings Inc (NYSEAMERICAN:INFU) Director Scott Shuda bought 9,548 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The stock was acquired at an average price of $3.23 per share, for a total transaction of $30,840.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
- [By Max Byerly]
LSV Asset Management cut its holdings in InfuSystem Holdings Inc (NYSEAMERICAN:INFU) by 22.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,200 shares of the medical instruments supplier’s stock after selling 36,400 shares during the quarter. LSV Asset Management owned approximately 0.54% of InfuSystem worth $437,000 at the end of the most recent quarter.
- [By Logan Wallace]
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Get Scynexis alerts:
Steady Activities: SCYNEXIS, Inc. (NASDAQ:SCYX), LPL Financial Holdings Inc. (NASDAQ:LPLA) (oracleexaminer.com) Do Analysts Think You Should Buy SCYNEXIS Inc (NASDAQ: SCYX) (stockspen.com) Notable Runner: SCYNEXIS, Inc. (SCYX) (nasdaqplace.com) Most Active Stocks Now: SCYNEXIS, Inc. (NASDAQ:SCYX), China Pharma Holdings, Inc. (NYSE:CPHI), Kala … (journalfinance.net) Overview on price to free cash flow: SCYNEXIS, Inc. (NASDAQ:SCYX), InfuSystem Holdings Inc. (NYSE:INFU) (stocksnewspoint.com)
Several research analysts have recently issued reports on the company. Roth Capital assumed coverage on Scynexis in a research note on Tuesday, May 8th. They set a “buy” rating and a $6.00 price target for the company. Seaport Global Securities assumed coverage on Scynexis in a research note on Tuesday, April 10th. They set a “buy” rating and a $4.00 price target for the company. Zacks Investment Research raised Scynexis from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, May 8th. HC Wainwright assumed coverage on Scynexis in a research note on Monday, May 7th. They set a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine raised Scynexis from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Scynexis currently has an average rating of “Buy” and an average target price of $4.45.
- [By Joseph Griffin]
Infusystem Holdings Inc (NYSEAMERICAN:INFU) major shareholder Meridian Ohc Partners, Lp purchased 40,548 shares of Infusystem stock in a transaction dated Monday, May 14th. The shares were acquired at an average cost of $2.76 per share, for a total transaction of $111,912.48. The transaction was disclosed in a filing with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.